In the Drug Profile by Vijayabhaskar Reddy Kandula, Homayoun Khanlou and Charles Farthing, Tipranavir: a novel second-generation nonpeptidic protease inhibitor, published in the February 2005 issue of Expert Review of Anti-infective Therapy (Expert Rev. Anti Infect.Ther. 3[1], 9-21 [2005]) the following sentence reads:
The Randomized Evaluation of Strategic Intervention in multidrug reSistant patients with Tipranavir (RESIST)-1 study was a Phase III, prospective, large scale, international, randomized trial comparing tipranavir 500/ritonavir 100 and standard-of-care boosted comparator PI (CPI)/ritonavir at 24 weeks.
The correct sentence is given below:
The Randomized Evaluation of Strategic Intervention in multidrug reSistant patients with Tipranavir (RESIST)-1 study was a PhaseIII, prospective, large scale, international, randomized trial comparing tipranavir 500/ritonavir 200 and standard-of-care boosted comparator PI (CPI)/ritonavir at 24 weeks.
The editors of Expert Review of Anti-infective Therapy and the authors would like to sincerely apologize for any inconvenience or confusion this may cause our readers.